304 studies found for:    biogen | biogen
Show Display Options
Rank Status Study
21 Suspended Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas
Conditions: Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Oligoastrocytoma, Mixed;   Gliosarcoma
Intervention: Genetic: Interferon-beta
22 Completed Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma, Low-Grade
Intervention: Drug: ibritumomab tiuxetan (Zevalin®)
23 Completed Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: Interferon-beta-1a;   Drug: methylprednisolone
24 Completed Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy
Condition: Multiple Sclerosis
Intervention: Drug: low immunogenic interferon-beta-1a
25 Terminated Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia (CLL)
Interventions: Drug: Lumiliximab + FCR;   Drug: FCR
26 Withdrawn BIIB014 Phase 2a Monotherapy
Condition: Parkinson's Disease
Interventions: Drug: active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.;   Drug: placebo
27 Completed BG9928 in Subjects With Hepatic Impairment
Condition: Hepatic Impairment
Intervention: Drug: BG9928
28 Recruiting Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
Condition: Relapsing Forms of Multiple Sclerosis
Intervention: Drug: dimethyl fumarate
29 Recruiting Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke
Condition: Acute Ischemic Stroke
Interventions: Biological: BG00002;   Drug: Placebo
30 Recruiting SFERA Study: Prospective, Single-arm, Open-label, Multi-center, Interventional Phase IV Study
Conditions: Relapsing-Remitting Multiple Sclerosis;   Clinical Isolated Syndrome (CIS);   Multiple Sclerosis
Intervention: Device: Interferon-beta-1a
31 Not yet recruiting Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With BG00012 or Standard of Care
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Interventions: Drug: BG00012 (Dimethyl Fumarate);   Other: Standard of Care (SOC) First Line Treatements
32 Recruiting Dimethyl Fumarate (DMF) Observational Study
Condition: Multiple Sclerosis
Intervention:
33 Not yet recruiting A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Healthy Volunteers and Subjects With Systemic Lupus Erythematosus
Conditions: Systemic Lupus Erythematosus;   Healthy
Interventions: Drug: BIIB059;   Drug: Placebo
34 Recruiting Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy
Condition: Progressive Multifocal Leukoencephalopathy
Intervention:
35 Terminated How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose
Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Drug: Interferon beta-1a
36 Completed A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers
Condition: Multiple Sclerosis
Interventions: Drug: Serum containing Avonex;   Drug: Serum Free Avonex
37 Recruiting Functional MRI in Lupus Nephritis
Condition: Lupus Nephritis
Intervention:
38 Completed Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Natalizumab;   Drug: Placebo
39 Completed Immunogenicity and Safety Study of Serum-Free Avonex
Condition: Multiple Sclerosis
Intervention: Drug: Interferon beta-1a
40 Not yet recruiting Pharmacokinetics of BIIB031 at 2 Vial Strengths
Condition: Severe Hemophilia A
Intervention: Biological: BIIB031 (rFVIIIFc)

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years